美股A股
StockGist
Back
8-K2026-03-04· grok-4-1-fast-non-reasoning

TCRX · TScan Therapeutics, Inc.

0001193125-26-089871

SEC filing

Summary

TScan Therapeutics, Inc. reported financial results for Q4 and full year 2025, with revenue of $2.6 million in Q4 and $10.3 million for the year, R&D expenses of $20.0 million in Q4 and $114.2 million for the year, and net loss of $23.0 million in Q4 and $129.8 million for the year. Cash and cash equivalents stood at $152.4 million as of December 31, 2025, sufficient to fund operations into the second half of 2027.

Key takeaways